Table 2.

Multivariable logistic regression analysis.

Variables	Coef.	SE	z.value	p.value	OR (95%CI)
Intercept	-5.926	0.096	-61.576	< 0.001*	0.003 (0.002-0.003)
Age
≥ 65 years	0.35	0.12	2.917	0.003*	1.419 (1.115-1.805)
Gender
Male	-0.172	0.06	-2.874	0.004*	0.842 (0.748-0.946)
Drugs
Pembrolizumab	1.83	0.109	16.847	< 0.001*	6.231 (5.008-7.669)
Nivolumab	1.248	0.116	10.785	< 0.001*	3.483 (2.757-4.342)
Carboplatin	0.814	0.143	5.71	< 0.001*	2.256 (1.687-2.952)
Enfortumab Vedotin	3.985	0.184	21.614	< 0.001*	53.76 (36.815-76.003)
Ipilimumab	1.344	0.204	6.584	< 0.001*	3.833 (2.502-5.589)
Bendamustine	1.84	0.201	9.167	< 0.001*	6.299 (4.144-9.134)
Atezolizumab	0.919	0.187	4.927	< 0.001*	2.507 (1.702-3.546)
Vemurafenib	2.264	0.198	11.461	< 0.001*	9.618 (6.375-13.869)
Pemetrexed	1.665	0.187	8.881	< 0.001*	5.285 (3.582-7.489)
Apalutamide	2.589	0.238	10.885	< 0.001*	13.311 (8.072-20.61)

OR, odds ratio; CI, confidence interval. The analysis was adjusted for age (reference: <65 years), gender (reference: female), and drugs (reference: all other anticancer drugs). * p < 0.01.